Table Of Content
Hey, congrats on the quarter and thanks for taking our questions. Sarcopenia is getting a lot of attention these days and some companies are talking about adding a storm to GLP. You certainly have your share of experiences with storm and sober opinion in general. Any thoughts on bringing back 5 to one one as an add-on strategy? Xaira’s internal platforms incorporate leading technologies and personnel which were spun out into Xaira at inception from Illumina’s long-standing functional genomics R&D effort. The company has also integrated a leading proteomics group from Interline Therapeutics.
Managers and Directors - Design Therapeutics, Inc.
But we're not going to let that be a gating factor. We would plan to start the study with vial and syringe and then transition on to the auto-injector. We would probably want to report what we have when the study is completed rather than cohort by cohort. Yes, it is, I think, getting to be more popular in the conversation. But it's a good point that 5 to one one compound is the most potent arm that we're aware of. And to the extent muscle loss is considered to be clinically relevant more.
DSGN
And I'll now turn the call over to Brian Lian for his initial comments. Xaira is building significant AI research capabilities spanning fundamental computational methods development and their application to biological discovery, the design of drug-like matter, and clinical development. Xaira was co-founded by Dr. David Baker, Professor of Biochemistry and Director of the Institute for Protein Design at the University of Washington School of Medicine. The company now employs a group of researchers who developed the leading models for protein and antibody design, RFdiffusion and RFantibody, while in Dr. Baker’s lab. Xaira’s broader team will advance these models and develop new methods that can connect the world of biological targets and engineered molecules to the human experience of disease. And I think we'll have to see what the data look like, but we'll be probably looking for a partner with the program, but hard to say without having a look at the data first.
Price Target and Rating
On average, they predict the company's stock price to reach $5.50 in the next year. This suggests a possible upside of 45.5% from the stock's current price. View analysts price targets for DSGN or view top-rated stocks among Wall Street analysts. With respect to what would be available and when will that those are the primary components of the data that we'll receive. We will be receiving probably little later data on paired biopsy reads, you know, what is someone's NASH, better, unchanged or worse at the end of the treatment period that that kind of thing since those take a little bit longer to evaluate. So we'll we haven't received the final data from the study.
Design Therapeutics Earnings History by Quarter
They don't really have abnormalities of very long-chain fatty acids, but we did see some reductions in very long-chain fatty acids in that prior Phase one experience. So if we can see somewhere in the mid to high 10s on the very long-chain fatty acid reduction that would be a pretty interesting, hopefully more than that. But that would be probably that the gating factor to consider further development in X-linked adrenoleukodystrophy.
BML Capital Management LLC Invests $2.73 Million in Design Therapeutics, Inc. (NASDAQ:DSGN)
In conjunction with my comments, I'd like to recommend that participants refer to Viking's Form 10 Q filing with the Securities and Exchange Commission, which we expect to file later today. I'll now go over our results for the first quarter ended March 31st, 2024. Research and development expenses were $24.1 million for the three months ended March 31st, 2024, compared to $11 million for the same period in 2023. The increase was primarily due to increased expenses related to manufacturing for our drug candidates, preclinical studies, clinical studies, stock-based compensation, salaries and benefits and services provided by third-party consultants. General and administrative expenses were $10 million for the three months ended March 31st, 2024, compared to $9.5 million for the same period in 2023. The increase was primarily due to increased expenses related to stock-based compensation, salaries and benefits and services provided by third-party consultants, partially offset by decreased expenses related to legal and patent services.
Price vs Fair Value
It showed in the somewhere in the 10s range for a NASH resolution and it did show some improvement in fibrosis. So to the extent we have a similar or better liver fat reduction, I think that would be sort of the range we would be looking at for NASH resolution and fibrosis improvement. And with respect to the overall market, yes, it does seem like there is a rapid expansion of the GLP-1 utilization. And so that probably does create some some some headwind on the uptake of new NASH drugs, but we've not had an approved drug for NASH. I think it's going to be really important to see how the first few quarters and mature there.
DSGN Stock Analysis - Frequently Asked Questions
Finally, during the quarter, Viking completed a public offering of common stock raising gross proceeds of approximately $630 million. These funds substantially strengthen the Company's balance sheet and will support our plans to aggressively develop our pipeline. I'll provide further details on our operations and development activities after we review our financial results for the first quarter of 2024. For that, I'll turn the call over to Greg Zante, Viking's Chief Financial Officer.
Design Therapeutics to Present at the 2022 Jefferies Cell and Genetic Medicine Summit
So it's hard to hard to really know how the FDA will judge the assessment of a plateau when the currently approved drugs did not reach that in there in their Phase 2b studies or so. That's that's one of the things we hope to learn a little bit about in the upcoming Type C meeting with the tox coverage, we're can we're finished with the chronic tox. So we don't have a limitation toxicity wise or GLP tox study limitation on duration.
A thumbnail of a daily chart is provided, with a link to open and customize a full-sized chart. You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Design Therapeutics' stock was trading at $2.65 on January 1st, 2024.
The consensus among Wall Street analysts is that investors should "hold" DSGN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in DSGN, but not buy additional shares or sell existing shares. View DSGN analyst ratings or view top-rated stocks. We are a biopharmaceutical company advancing novel, small molecule therapeutic candidates designed to bring functional cures to serious genetic diseases with long-standing unmet need.
So in the pharmacologic setting versus the regular diet and exercise setting, it could be something that's a that's really useful. Design Therapeutics's earnings are expected to decrease from ($1.26) per share to ($1.46) per share in the next year. Enter your email address below to receive the latest news and analysts' ratings for Design Therapeutics and its competitors with MarketBeat's FREE daily newsletter.
Jump Financial LLC now owns 46,700 shares of the company's stock worth $110,000 after acquiring an additional 34,561 shares during the last quarter. 56.64% of the stock is owned by hedge funds and other institutional investors. 7 analysts have issued 1-year target prices for Design Therapeutics' stock. Their DSGN share price targets range from $4.00 to $6.00.
Design Therapeutics director buys $4.9k in stock By Investing.com - Investing.com
Design Therapeutics director buys $4.9k in stock By Investing.com.
Posted: Mon, 25 Mar 2024 07:00:00 GMT [source]
And do you think you'll have enough data to support less frequent dosing? And then what are your latest thoughts on a Phase IIb study? And then I had a follow-up question, if I could. Two eight zero nine, what's the general translatability of kind of the 12 week MRI PDFF result into later histology endpoints and on are you planning to move the program into mass program into Phase three yourself? And then maybe as a third and final question, how do you think that thyroid beta agonist market will develop. There's kind of been some recent evidence that GLP ones, both dual GLP-1 and GIP.
And you know, I think a couple of things we're right now in this very acute stage where these compounds have just been recently approved for weight loss and there is just overwhelming demand and the supply isn't quite there. We don't consider that to be a terminal state. We do see from the existing companies in the space, it ramp up in manufacturing capacity. We know on the contractor side, there is a massive attention being paid paid to this this issue. And so I think the supply dynamics will probably evolve over the next few years, still going to be a difficult challenge, but I think we're not in a permanent shortage state, we don't think. So with the translatability for liver fat to histologic improvement.
No comments:
Post a Comment